Research programme: glycosylated antibodies - Roche Glycart
Alternative Names: GA 301; GlycoMAbLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator GLYCART Biotechnology
- Developer Roche; Roche Glycart
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Switzerland
- 24 Mar 2004 Preclinical trials in Cancer in Switzerland (unspecified route)